Image

Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

Recruiting
22 years and older
All
Phase N/A

Powered by AI

Overview

This study will evaluate hiatal hernia recurrence rate and post-operative complications following the use of OviTex Core Resorbable or OviTex 1S Resorbable.

Description

This prospective, open-label, multicenter, non-randomized, post-market study will enroll up to 133 subjects in the United States. Patients undergoing an elective hiatal hernia repair and who meet all eligibility criteria will be enrolled in the study. Subjects will undergo minimally invasive procedures for hiatal hernia repair with the use of OviTex Core Resorbable or OviTex 1S Resorbable for reinforcement. Subjects will have clinical follow-up through 5 years. Data collected in this study will be compared to a literature control at 24 months.

Eligibility

Inclusion Criteria:

  1. Patient is a candidate for an elective robotic or laparoscopic primary hiatal hernia repair with the use of OviTex Core Resorbable or OviTex 1S Resorbable.
  2. Patient is willing and able to voluntarily sign the IRB-approved Informed Consent Form for the study.
  3. Patient is at least 22 years old at the time of surgery.
  4. Patient is not pregnant and not planning to become pregnant during the duration of the study (5 years).
  5. Patient is able and willing to comply with the study requirements including completion of patient questionnaires and clinic evaluations.

Exclusion Criteria (Baseline):

  1. Patient has a Body Mass Index (BMI) of ≥ 35.
  2. Patient meets the Centers for Disease Control (CDC) Surgical Site Infection (SSI) Wound Classification Class IV (Dirty-Infected) criteria.
  3. Patient has a Type I hiatal hernia.
  4. Patient has a life expectancy of less than five years making it unlikely that the subject will successfully achieve five-year follow-up.
  5. Patient is a current nicotine user (including smokeless, vaporized, etc.)
  6. Patient has a history of illicit drug or alcohol abuse (in the last three years).
  7. Patient has an allergy to ovine-derived products or a known sensitivity to polyglycolic acid (PGA).
  8. Patient has an allergy to barium.
  9. Patient's surgery will include the use of an anti-reflux implantable device (LINX, etc.).
  10. Patient's surgery requires the use of an additional mesh device or a pledget for reinforcement.
  11. Patient has participated in another gastrointestinal (GI) clinical study within the past 30 days or is currently involved in another clinical study excluding observational and registry studies.
  12. Patient had previous surgery at the gastroesophageal junction.
  13. Patient had a prior hiatal hernia repair.
  14. Patient has an incarcerated hernia that requires emergent intervention.
  15. Patient is a prisoner.

Exclusion Criteria (Intra-operative):

  1. Patient is unable to receive OviTex Core Resorbable or OviTex 1S Resorbable at time of surgery.
  2. Surgery requires the use of an additional mesh device or a pledget for reinforcement.
  3. Surgery includes the use of an anti-reflux implantable device (LINX, etc.).
  4. Surgery performed as an open procedure.
  5. Patient has a condition, which in the Investigator's opinion, may put the patient at increased risk, confound study data, or interfere significantly with the patient's participation in the study.

Study details
    Hiatal Hernia

NCT07070115

Tela Bio Inc

12 August 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.